Compare IDCC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDCC | LQDA |
|---|---|---|
| Founded | 1972 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 5.5B |
| IPO Year | 2007 | 2020 |
| Metric | IDCC | LQDA |
|---|---|---|
| Price | $325.80 | $33.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $462.67 | $51.50 |
| AVG Volume (30 Days) | 166.1K | ★ 3.4M |
| Earning Date | 10-29-2026 | 11-02-2026 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | ★ 5.51 | 1.26 |
| Revenue | ★ $307,404,000.00 | $158,320,000.00 |
| Revenue This Year | N/A | $325.27 |
| Revenue Next Year | N/A | $9.02 |
| P/E Ratio | $60.41 | ★ $21.28 |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $249.14 | $21.97 |
| 52 Week High | $412.60 | $93.61 |
| Indicator | IDCC | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 45.79 | 33.00 |
| Support Level | $317.76 | $30.35 |
| Resistance Level | $351.31 | $42.62 |
| Average True Range (ATR) | 9.64 | 3.35 |
| MACD | -0.76 | -1.44 |
| Stochastic Oscillator | 17.94 | 21.55 |
InterDigital Inc is a research and development company focused on wireless, Video, Artificial Intelligence, and related Technologies. It designs and develops technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. The majority of revenue is generated from fixed-fee patent license agreements, with a smaller portion coming from variable royalty agreements. Geographically, it operates in the United States, China, South Korea, Japan, Taiwan, and Europe, with the majority is from China.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.